Original title: Mechanical Recanalization with Flow Restoration in Acute Ischemic Stroke. The Mechanical Recanalization with Flow Restoration in Acute Ischemic Stroke (ReFlow) Study. Reference: Christian Roth et al. J Am Coll Cardiol Intv 2013. Article in press. The intravenous tissue-type plasminogen activator (tPA) has proved to reduce morbidity and mortality in patients with acute ischemic stroke. In the…
Endovascular therapy after t-PA: no additional benefit for patients with acute stroke
Original title: Endovascular Therapy after Intravenous t-PA versus t-PA Alone for Stroke. Interventional Management of Stroke (IMS) III. Reference: Joseph P. Broderick et al. N Engl J Med 2013.DOI: 10.1056/NEJMoa1214300 Tissue plasminogen activator (t-PA; alteplase [Activase, Genentech, or Actilyse, Boehringer Ingelheim]) is the only reperfusion therapy proved useful for patients with acute ischemic stroke and its clinical efficacy…
Cilostazol reduces restenosis in infrapopliteal angioplasty
Original title: Impact of Cilostazol on Angiographic Restenosis after Balloon Angioplasty for Infrapopliteal Artery Disease in Patients with Critical Limb Ischemia Reference: Y. Soga et al. European Journal of Vascular and Endovascular Surgery 44 (2012) 577e581. Angioplasty is regularly used for patients with critical limb ischemia where restenosis is a great limitation, especially in infrapopliteal territory. The use…
High-dose atorvastatin for prevention of contrast nephropathy
Original title: Impact of a High Loading Dose of Atorvastatin on Contrast-Induced Acute Kidney Injury. Reference: Quintavalle et al. CIRCULATIONAHA.112.10331, 2012 Patients included in this study represent a subgroup with chronic renal failure (CRF) enrolled in the NAPLES II trial who were randomized to atorvastatin 80 mg 24 hours before angioplasty, (n = 202) versus the control group…